222 related articles for article (PubMed ID: 30319427)
1. Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.
Zazuli Z; Vijverberg S; Slob E; Liu G; Carleton B; Veltman J; Baas P; Masereeuw R; Maitland-van der Zee AH
Front Pharmacol; 2018; 9():1111. PubMed ID: 30319427
[No Abstract] [Full Text] [Related]
2. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of
Zazuli Z; Otten LS; Drögemöller BI; Medeiros M; Monzon JG; Wright GEB; Kollmannsberger CK; Bedard PL; Chen Z; Gelmon KA; McGoldrick N; Kitchlu A; Vijverberg SJH; Masereeuw R; Ross CJD; Liu G; Carleton BC; Maitland-van der Zee AH
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31083486
[TBL] [Abstract][Full Text] [Related]
3. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
[TBL] [Abstract][Full Text] [Related]
5. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study.
Zazuli Z; de Jong C; Xu W; Vijverberg SJH; Masereeuw R; Patel D; Mirshams M; Khan K; Cheng D; Ordonez-Perez B; Huang S; Spreafico A; Hansen AR; Goldstein DP; de Almeida JR; Bratman SV; Hope A; Knox JJ; Wong RKS; Darling GE; Kitchlu A; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; Ross CJD; Carleton BC; Egberts TCG; Herder GJM; Deneer VHM; Maitland-van der Zee AH; Liu G
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834585
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
7. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
8. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
9. Association Between
Boldrin E; Malacrida S; Rumiato E; Battaglia G; Ruol A; Amadori A; Saggioro D
Front Oncol; 2019; 9():85. PubMed ID: 30847299
[TBL] [Abstract][Full Text] [Related]
10. Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma.
Cui QK; Zhu JX; Liu WD; Wang YH; Wang ZG
Pak J Med Sci; 2014; 30(6):1409-14. PubMed ID: 25674148
[TBL] [Abstract][Full Text] [Related]
11. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
13. Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).
Driessen CM; Ham JC; Te Loo M; van Meerten E; van Lamoen M; Hakobjan MH; Takes RP; van der Graaf WT; Kaanders JH; Coenen MJH; van Herpen CM
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30999660
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
Dahal A; Bellows BK; Sonpavde G; Tantravahi SK; Choueiri TK; Galsky MD; Agarwal N
Am J Clin Oncol; 2016 Oct; 39(5):497-506. PubMed ID: 24824144
[TBL] [Abstract][Full Text] [Related]
15. Systematic review on the association between ERCC1 rs3212986 and ERCC2 rs13181 polymorphisms and glioma risk.
Zhou CX; Zhao JH
Genet Mol Res; 2015 Mar; 14(1):2868-75. PubMed ID: 25867436
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
17. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.
Tzvetkov MV; Behrens G; O'Brien VP; Hohloch K; Brockmöller J; Benöhr P
Pharmacogenomics; 2011 Oct; 12(10):1417-27. PubMed ID: 21902499
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients.
Garcia SL; Lauritsen J; Zhang Z; Bandak M; Dalgaard MD; Nielsen RL; Daugaard G; Gupta R
JNCI Cancer Spectr; 2020 Jun; 4(3):pkaa032. PubMed ID: 32617516
[TBL] [Abstract][Full Text] [Related]
20. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients.
Zhang J; Zhou W
Food Chem Toxicol; 2012 Jul; 50(7):2289-93. PubMed ID: 22525860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
